In light of the concrete possibility of post-surgery spreading, these results should bolster the synthesis of CX3CR1 inhibitors and their pre-clinical and clinical testing, to ultimately conceive new adjuvant therapeutic approaches and promote a paradigm shift in the management of breast cancer patients. This evidence concerns the gene CX3CR1 and breast cancer.